E-mail

E-mail a Wiley Online Library Link

Allison Ackerman, Oliver Klein, David F. McDermott, Wei Wang, Nageatte Ibrahim, Donald P. Lawrence, Anasuya Gunturi, Keith T. Flaherty, F. Stephen Hodi, Richard Kefford, Alexander M. Menzies, Michael B. Atkins, Georgina V. Long and Ryan J. Sullivan Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors Cancer 120

Article first published online: 27 FEB 2014 | DOI: 10.1002/cncr.28620

Four new therapies have been approved by the US Food and Drug Administration from 2011 to 2013 for the treatment of metastatic melanoma, yet there are little data to guide sequencing of these therapies. In a retrospective analysis, immunotherapy does not alter treatment effect of the BRAF inhibitor vemurafenib, and treatment with an immunotherapeutic, ipilimumab, is not effective following prior therapy with vemurafenib in patients with BRAF-mutant, metastatic melanoma.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH